Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530284 | 1.00 | ABL1 (0.48) | ABL1KCNH2RAB9AWDR5SCN9A | |
| SCHEMBL30530275 | 0.95 | ABL1 (0.47) | ABL1KCNH2RAB9AWDR5SCN9A | |
| SCHEMBL20188432 | 0.95 | ABL1 (0.47) | ABL1KCNH2RAB9AWDR5SCN9A | |
| SCHEMBL21799047 | 0.94 | ABL1 (0.46) | ABL1KCNH2RAB9AWDR5LRRK2 | |
| SCHEMBL30530288 | 0.94 | ABL1 (0.46) | ABL1KCNH2RAB9AWDR5LRRK2 | |
| SCHEMBL21799079 | 0.93 | ABL1 (0.51) | ABL1KCNH2RAB9ASCN9A | |
| SCHEMBL30114877 | 0.93 | ABL1 (0.51) | ABL1KCNH2RAB9ASCN9A | |
| SCHEMBL21799100 | 0.92 | ABL1 (0.55) | ABL1KCNH2RAB9ASCN9AWNT3A | |
| SCHEMBL30114863 | 0.92 | ABL1 (0.55) | ABL1KCNH2RAB9ASCN9AWNT3A | |
| SCHEMBL30530278 | 0.91 | RAB9A (0.49) | RAB9AWDR5WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544685-B1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEV CT BIOTECHNOLOGY (TW) | 2023-01-04 | — | — | EP | claimed |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-10-06 | — | — | US | claimed |
| US-20200079753-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-03-12 | — | — | US | claimed |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-10-06 | — | — | US | disclosed |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-10-06 | — | — | US | disclosed |
| US-20200079753-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079753-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | SHH, GLI1, SMO | ABL1 1218/4885KCNH2 2640/4885RAB9A 388/4885 |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | SHH, GLI1, NR1H4 | ABL1 1395/4885KCNH2 1702/4885RAB9A 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.